Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials: Erratum

No authors listed

Published Erratum

No authors listed. J Acquir Immune Defic Syndr. 2020.

. 2020 Jul 1;84(3):e21.

doi: 10.1097/QAI.0000000000002394.

Abstract

Supplemental Digital Content is Available in the Text.

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Brandon DJ, Underwood M, Tenorio AR, Pappa KA, Wynne B, Gartland M, Aboud M, van Wyk J, Smith KY. Cahn P, et al. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):310-318. doi: 10.1097/QAI.0000000000002275. J Acquir Immune Defic Syndr. 2020. PMID: 31834000 Free PMC article. Clinical Trial.

1. Cahn P, Madero JS, Arribas JR, et al. Durable efficacy of Dolutegravir Plus lamivudine in antiretroviral treatment–naive Adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical Trials. J Acquir Immune Defic Syndr. 2020;83:310–318. - PMC - PubMed